Healthcare Industry News:  Matrix Laboratories 

Biopharmaceuticals Generics FDA

 News Release - January 30, 2007

Mylan Announces Final FDA Approval for Albuterol Sulfate Extended-Release Tablets

PITTSBURGH, Jan. 30 (HSMN NewsFeed) -- Mylan Laboratories Inc. (NYSE: MYL ) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Extended-release (ER) Tablets, 4mg (base) and 8mg (base).

Albuterol Sulfate ER Tablets are the generic version of Dava Pharmaceutical's VoSpire ERĀ®, which had U.S. sales of approximately $19 million for the same strengths in the 12-month period ending Sept. 30, 2006, according to IMS Health.

This product will be shipped immediately.

Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories Inc., and a controlling interest in Matrix Laboratories Limited, India. Mylan develops, licenses, manufactures, markets and distributes an extensive line of generic and proprietary products.

For more information about Mylan, please visit

Source: Mylan Laboratories

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.